Overall, these results suggest that KCNN4 expression is correlated with TMB, MSI, and ICGs in multiple pan-cancer datasets, combined with evidence from TIDE, convincingly indicating that it could be a robust and reliable biomarker for predicting the responses of cancer cells to immunotherapy. This evidence concerns the gene KCNN4 and cancer.